Conatus Raises $20M for Hepatitis C Studies

Xconomy San Diego — 

San Diego’s Conatus Pharmaceuticals, which specializes in developing drugs for liver disease and cancers, said it closed on a $20 million block of equity funding, which was led by a new investor, AgeChem Venture Fund of Montreal. Existing investors Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and the Roche Venture Fund also participated. In a statement Friday, Conatus said it plans to use the proceeds to advance development of a new drug for treating hepatitis C. Conatus, which was founded in 2005, said the Series B financing will remain open as other potential investors study the deal.